FDA
-
-
-
-
-
-
-
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
-
-
-
-
-
-
-
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene’s (CLNN) New Drug On Accelerated Approval Pathway: Benchmark
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
-
322,882 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

